Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.

Gialama F, Maniadakis N.

Vasc Health Risk Manag. 2013;9:575-92. doi: 10.2147/VHRM.S50831. Epub 2013 Oct 7. Review.

2.

The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.

Borghi C, Cicero AF.

High Blood Press Cardiovasc Prev. 2012 Mar 1;19(1):19-31. doi: 10.2165/11632100-000000000-00000. Review.

PMID:
22670584
3.
4.

Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A.

Clin Ther. 2007 Jul;29(7):1508-23.

PMID:
17825702
5.

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.

PMID:
17076969
6.

[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].

Frei A, Palmer AJ, Burnier M, Hess B.

Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. German.

PMID:
16570646
7.

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.

PMID:
15101793
8.

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.

Ekman M, Bienfait-Beuzon C, Jackson J.

J Hum Hypertens. 2008 Dec;22(12):845-55. doi: 10.1038/jhh.2008.76. Epub 2008 Jul 17.

PMID:
18633426
10.

The cost-effectiveness of irbesartan for hypertension.

Borghi C, Urso R, Cicero AF.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):199-207. doi: 10.1586/14737167.2015.1018894. Epub 2015 Feb 23. Review.

PMID:
25703678
11.
12.

[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German.

PMID:
16868875
14.

Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.

Bramlage P, Schindler C.

Expert Opin Pharmacother. 2010 Mar;11(4):521-35. doi: 10.1517/14656560903512962. Review.

PMID:
20030566
15.

[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, de Alvaro F; Grupo de Estudio Colaborativo IDNT.

Nefrologia. 2004;24(3):231-8. Spanish.

16.

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.

PMID:
17877649
17.

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, Lewis EJ; Collaborative Study Group.

Clin Ther. 2003 Jul;25(7):2102-19.

PMID:
12946554
18.

[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.

Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. German.

PMID:
14703575
20.

Clinical overview of irbesartan: expanding the therapeutic window in hypertension.

Man in't Veld AJ.

J Hypertens Suppl. 1997 Dec;15(7):S27-33.

PMID:
9532518

Supplemental Content

Support Center